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Abstract
We used the GEnSeMBLE Monte Carlo method to predict ensemble of the 20 best packings (helix
rotations and tilts) based on the neutral total energy (E) from a vast number (10 trillion) of
potential packings for each of the 4 subtypes of the adenosine G protein-coupled receptors
(GPCRs), which are involved in many cytoprotective functions. We then used the DarwinDock
Monte Carlo methods to predict the binding pose for the human A3 adenosine receptor (hAA3R)
for subtype selective agonists and antagonists.
We find that all four A3 agonists stabilize the 15th lowest conformation of apo-hAA3R while also
binding strongly to the 1st and 3rd. In contrast the four A3 antagonists stabilize the 2nd or 3rd
lowest conformation. These results show that different ligands can stabilize different GPCR
conformations, which will likely affect function, complicating the design of functionally unique
ligands.
Interestingly all agonists lead to a trans χ1 angle for W6.48 that experiments on other GPCRs
associate with G-protein activation while all 20 apo-AA3R conformations have a W6.48 gauche+
χ1 angle associated experimentally with inactive GPCRs for other systems. Thus docking
calculations have identified critical ligand-GPCR structures involved with activation.
We find that the predicted binding site for selective agonist Cl-IB-MECA to the predicted
structure of hAA3R shows favorable interactions to three subtype variable residues, I2536.58,
V169EL2, and Q167EL2, while the predicted structure for hAA2AR shows weakened to the
corresponding amino acids: T2566.58, E169EL2, and L167EL2, explaining the observed subtype
selectivity.
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Introduction
Adenosine receptors (ARs), G protein-coupled receptors (GPCRs) with 7 transmembrane
(TM) spanning helices,1 are involved in many cytoprotective functions, making them
important pharmacological targets for treatment of a variety of diseases because of their key
roles in controlling numerous physiological processes. Many therapeutic agents under
development for treatment of central nervous system disorders, inflammatory diseases,
asthma, kidney failure, and ischemic injuries exert their effects via direct interactions with
ARs. However the target is often just one of the four subtypes of human ARs, designated
A1, A2A, A2B, and A3. The A2A and A2B adenosine subtypes are linked to Gs proteins,
increasing the intracellular levels of cAMP upon receptor activation, while the A1 and A3
adenosine subtypes are linked to Gi proteins inhibiting cAMP formation. The A3 and A2B
subtypes can also activate the inositol phosphate formation through coupling to Gq proteins.
2 Thus activation of human adenosine A1 receptor (hAA1R), decreases the oxygen demand
of a stressed organ by slowing the heart rate. Conversely, activation of hAA2AR can increase
oxygen supply via vasodilation and inhibition of platelet aggregation. Also a development of
anti-Parkinson’s agents utilizes hAA2AR antagonists.3 On the other hand hAA2BR
activation, has an angiogenic effect, while activation of the cardiac hAA3R preconditions
cardiac myocytes against ischemic damage4 and protects against toxicity. This can be seen
in the case of the cardiotoxic effects of the anticancer drug doxorubicin.5 Moreover, hAA3R
antagonists are of interest as potential anti-glaucoma agents.6 In particular, hAA3R agonists,
such as IB-MECA (N6-(3-Iodobenzyl)-5’-N-methylcarboxamidoadenosine) and Cl-IB-
MECA (2-Chloro-N6-(3-iodobenzyl)-5’-N-methylcarboxamidoadenosine) that were
developed in the Jacobson lab. at National Institute of Health, are now advancing into Phase
II clinical trials for treating diseases such as cancer, arthritis, and psoriasis.2
Since these AR targets generally involve just one subtype, it is essential that new ligands be
developed that are subtype specific. To design such subtype-selective drugs requires detailed
3D predicted structures for all four receptors and for the low-lying conformation that might
be stabilized by the prospective new ligands. Particularly this is important for agonists, since
it is likely that the process by which agonists activate the G-Protein involve the agonist
interacting with more than one GPCR conformation.
Previously, we reported the predicted structures of the human adenosine subtypes (A1, A2A,
A2B, and A3) based on the human β2 adrenergic receptor template (PDB ID: 2rh1). There we
found that the predicted binding energies of 8 antagonists to the predicted structure of A2A
were found to correlate quite well with experiment. In addition the predicted binding sites
for ZM241385 inverse agonist bound to hAA2AR7 compares well with x-ray crystal
structure.
Here, we use the improved GEnSeMBLE method to predict new structures for the four
subtypes (A1, A2A, A2B, and A3) of human AR starting with a template based on the x-ray
structure for ZM241385 bound to hAA2AR (PDB ID: 3eml). GEnSeMBLE selects from a
vast number (10 trillion) of potential packings a final ensemble of the 20 best packings
(helix rotations and tilts) based on predicted total E, that we consider might play a role in
binding to various ligands and in activation.
In addition, we used the DarwinDock Monte Carlo method to predict the binding sites and
energies for four agonists and four antagonists (structures shown in Chart 1) to each of the
20 most stable conformations of hAA3R. We find that all four agonists prefer the 15th
conformation of the apo-hAA3R, whereas the four antagonists prefer either the 2nd or 3rd.
Moreover all four agonists have the W6.48 the horizontal orientation (trans χ1) believed
from experiments on other GPCRs to be associated with activation, while 20 lowest
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conformations of the apo-hAA3R have W6.48 in the vertical orientation (gauche+ χ1)
believed from experiments on other GPCRs to be inactive.8-10
These predictions confirm the high selectivity toward hAA3R for the agonist, Cl-IB-MECA,
and the high selectively for adenosine toward hAA2AR, the endogenous agonist, validating
the accuracy of these methods for explaining the subtype selectivity.
We expect that improved understanding of how these GPCRs function at the molecular level
will be useful for the development of novel classes of AA3R-targeted drugs.
Materials and Methods
In order to predict the 3D structures for the various conformations needed to understand the
function of GPCRs and help design new ligands, we use the GEnSeMBLE (GPCR
Ensemble of Structures in Membrane BiLayer Environment) method, which provides a very
complete sampling over possible rotations and tilts and leading to a ensemble of low lying
predicted structures expected to include those conformations energetically accessible for
binding of ligands. This replaces our earlier MembStruk method.11
We now use the DarwinDock to predict the binding sites of ligands to the GPCRs. This
replaces our earlier HierDock12 and MSCDock13 methods, providing a much more complete
sampling of possible poses. These earlier methods were validated by a series of applications
to various GPCRs: human D2 dopamine receptor (DR),14 human β2 adrenergic receptor,15,
16 human M1 muscarinic receptor,17 human Chemokine (C-C) motif receptor 1 (CCR1),18
mouse MrgC11 (Mas Related Gene) for the molluscan peptide FMRF-amide (FMRFa),19, 20
human prostanoid DP receptor,21 and human Serotonin 2C 22 receptor.
GEnSeMBLE consists of the following key steps:
1. Generation of the 7-transmembranic helix (TMH) bundle.
1. PredicTM: To predict the seven TM domains our current approach
(PredicTM) combines hydrophobicity analysis with information from
multiple sequence alignments, involving six steps; i) retrieval of similar
protein sequences from a database, ii) multiple sequence alignment of
sequences using the MAFFT23 program, iii) Hydrophobic profile in the
multiple sequence alignment (using the thermodynamic and biological
hydrophobic scales from White and von Heijne24, 25), iv) initial TMH
region predictions in Fig. S1 of Supporting Information, v) Application of
capping rules and extension of consensus helices based on the APSSP226
and PORTER27 servers, vi) identification of hydrophobic centers in Table
S1 of Supporting Information. More details are described in Supporting
Information.
2. OptHelix: To predict the kinks often induced by proline residues, we
replace the longer side chains and helix termini (save Ser and Thr near
Pro) with alanines and carry out 2 ns of molecular dynamics (MD) on each
helix, followed by a restoration of the correct side chains using
SCREAM28 and a minimization of the structure. This procedure works
well and predicts helices within 1-2 Å of the crystal.
3. Template Generation: To pack the 7 helices from OptHelix into a bundle
requires that six quantities be specified for each helix: the x-, y-, and z-
coordinate of the hydrophobic center, the tilt (θ) of each axis from the z-
axis, the azimuthal orientation (φ) of this tilt; and the rotation (η) of the
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helix about the helical axis, when the x-axis is defined along the axis from
the center point of TMH3 to the center point of TMH2 in the midplane
(see Fig. S2 of Supporting Information). We obtain z from PredicTM
while θ, φ, η are sampled as described below. The remaining two
coordinates, x and y, for each helix are taken from template structures,
either experimental or validated theoretical. Currently, we can consider
eight such templates: bovRho (PDB ID: 1u19)29, hβ2-adrenergic receptor
(2rh1),10 hAA2AR (3eml),9 turkey β1-adrenergic receptor (2vt4),8 and
bovine opsin (3cap) 30 from experiment, as well as the predicted and
validated DP Prostaglandin,21 MrgC11,19, 20 and CCR1 Chemokine18
receptors. GEnSeMBLE allows for each of these templates to be used in
separate predictions, providing an ensemble of bundles from which we can
select on the basis of bundle E or ligand binding E.
As a reference for the rotation angle (η) of each helix, we use a highly
conserved residue (N1.50, D2.50, W4.50, P5.50, P6.50, and P7.50) in
family A and D3.32 that is conserved among amine receptors, and match
the rotation angle of its Cα projection on the x-y plane to that of the
corresponding residue in the template structure. The helical axis for
rotation is defined as the one corresponding to the least moment of inertia
axis obtained using all backbone atoms.
2. Homology of the 7-TMH bundle.
1. HomologyTM: In addition to PredicTM helices, we also generated the
homology TM helices where we took advantage of the high sequence
identity of hAA1R, hAA2BR and hAA3R with the x-ray structure of
hAA2AR, both at the whole sequence (A1: 45.39%, A2B: 38.59%,
A3:31.31%) and TMH region (A1: 68.84%, A2B: 59.94%, A3: 51.01%)
level. Using the sequence alignment of each subtype to hAA2AR, the side
chain of each amino acid in the isolated helices from the hAA2AR bundle
was mutated to the corresponding amino acid of the given subtype by our
rotamer placement method SCREAM28.
For hAA2AR, we constructed a TMH bundle from the x-ray structure,
removing the N/C terminals and loops. The following residue number
ranges describe the final TMH regions with α-helix structure: 5-32 for
TMH1, 41-67 for TMH2, 75-106 for TMH3, 119-140 for TMH4, 175-204
for TMH5, 222-258 for TMH6, and 269-291 for TMH7.
2. OptimizeHelix: The geometry of each isolated helix was optimized by
100 steps with 0.5 terminal gradient using DREIDING 3 force field (FF)
(referred to as DREIDING-III or D3FF)31 to remove seriously bad
contacts among helices.
3. BiHelix Optimization of the rotation angles
1. BiHelix: The next step is to optimize the rotation angles (η) for each of
the 7 TMHs. The general procedure is to simultaneously rotate each TMH
through 360° in 30° increments, leading to (12)7 = 35,000,000 configures
(Fig. S2 of Supporting Information). To rapidly identify the best 1000 of
these, we first consider each helix interacting with just one other helix,
leading to 12*12 =144 combinations for each of the 12 pairs of interacting
helices (1-2, 2-4, 4-5, 5-6, 6-7, 1-7, 1-3, 2-3, 3-4, 3-5, 3-6, 3-7). For each
of these 144*12 pairs we optimize the sidechains using SCREAM.28 Then
these 1728 “mean field” numbers are used to estimate the energies of all
Kim et al. Page 4
Proteins. Author manuscript; available in PMC 2012 June 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
35,000,000 conformations, from which we pick the best 1000 by total E
for subsequent CombiHelix analysis.
SCREAM uses a library of residue conformations ranging from a root
mean square of a Cα atom (CRMS) diversity of 0.4 Å to 1.6 Å in
conjunction with a Monte Carlo sampling using full valence, hydrogen
bond and electrostatic interactions, but with special van der Waals (vdW)
potentials that somewhat reduce the penalty for contacts that are slightly
too short while retaining the normal attractive interactions at full strength.
With SCREAM, we find that we can now base the selections on the total
E, Escream, without separate considerations for valence, electrostatic,
hydrogen bond, and vdW terms.
However for the ARs, we restricted rotations ± 45° rotation with 15°
increments resulting in (7)7 = 823,543 combinations. Then we used the
BiHelix to combine the Escream energies of the 49 combinations for each
helix pair (using a total of 49 × 12 helix pairs = 551 energies) to estimate
the E for all 823,543 conformational combinations for the ± 45° rotational
range.
2. CombiHelix: The top 1,000 predicted structures from BiHelix analysis are
built explicitly using the rotations specified for each helix in the
combination. The multiple rotational combinations are minimized by their
side chains using SCREAM in order to evaluate the total E of the
optimized multi-helix bundle. To avoid overestimation of long-range
charge interaction, we neutralize the system by adding protons into the
negatively charged residues, Asp and Glu, or by deleting protons from the
positively charged amino acids, Lys and Arg. After neutralizing the top
100 predicted structures based on the charged total E, the final 100 low E
predicted structures are ordered by the neutral total E of the optimized
multi-helix bundle.
We validated this procedure for all five experimental GPCR structures.
Using the BiHelix method, we estimated the energies for all (12)7 ~ 35
million combinations from 0 to 360° angles by 30° increments. The
experimental structure corresponds to the angle rotation combination
0_0_0_0_0_0_0 (the first zero corresponds to TMH 1, the second zero
corresponds to TMH 2, and so on). The results indicate that the crystal
structures rank as the top 1 lowest E predicted structure at the end of the
procedure for all five cases.
4. SuperBiHelix optimization of the rotation and tilt angles
1. SuperBiHelix: For the lowest E predicted structures from BiHelix for
each of the 4 subtypes, we determine the optimum rotations (θ, φ, η) for
the packing of the 7 helices into a 7-TMH bundle. Here we considered a
±10° sampling of θ tilt angle and a ±30° sampling of both φ and η angles,
leading to a total of (3×5×5)7 ~ 10 quadrillion combinations. To make this
huge sampling computationally feasible, use SuperBiHelix sampling as
follows. For each of the 12 pairs of helices, we sample all combinations of
θ, φ, η for each of the (3×5×5)2 = 5,625 rotational-tilt combinations of
each of the 12 pairs. In each case we optimize the side chains using
SCREAM28 with all-atom DREIDING FF.31
The total energies for each of these (12)×(5,625) helix pair combinations
are used to estimate the E for all 10 quadrillion 7-TMH bundle
Kim et al. Page 5
Proteins. Author manuscript; available in PMC 2012 June 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
conformational combinations using the following procedure. In order to
determine the conformations for each helix that lead to low E bundles.
Then the 7-TMH bundle is partitioned into three quadhelix bundles. Next,
the total energies of the three quadhelix bundles are calculated using the
BiHelical energies. This is feasible because only 3× (3×5×5)4 ≈ 108
bundle energies must be calculated. The 2,000 predicted structures with
the lowest E for each quadhelix are listed by increasing E and used to
select the top 36 orientations preferred by each helix. Finally, these
conformations are used to calculate the E of (36)7 ≈ 8 × 1010 full bundles
and output the 1000 best E predicted structures from this procedure.
2. SuperComBiHelix: The top 1,000 predicted structures from the
SuperBiHelix analysis were built explicitly using the rotations and tilts
specified for each helix in the combination (they will take different
conformations than were found in the BiHelical mode). The 7 TMH
predicted structure is then minimized for 10 steps. This ensemble of low-
lying predicted structures from SuperComBiHelix is used to in the
docking studies for various agonists and antagonists.
The 100 lowest E predicted structures based on the charge total E, are then
neutralized and reordered by the neutral total E of their optimized multi-
helix bundle. From this we select the ensemble of ~20 low-E predicted
structures, each of which is docked to agonists, antagonists, and inverse
agonists to provide the structures likely to be involved in GPCR
activation.
This procedure has been validated by applying it to all GPCRs.7
Our goal in developing these in silico methods is to predict the 3D
structures of GPCRs that are remote from the systems currently available
from experiment. Thus we have emphasized first principles approaches
rather than homology methods. We believe that the studies reported in this
paper indicate the potential power of this approach. Thus we find that the
ensemble of configurations of the apo-A3 provides the flexibility to bind
both to agonists and antagonists. As experimental methods are developed
to obtained x-ray structures of agonist-bound systems, we will obtain
quantitative measures for the accuracy of our predictions.
5. Ligand docking
The lowest E predicted structures of the hAA2AR and hAA3R from BiHelix were
used for docking several ligands, using the DarwinDock. The structure and charges
of the ligands in Chart 1 were calculated using quantum mechanics (B3LYP with
the 6-311G** basis set). The Histidines forming the H-bonding with Glu were
treated as the protonated His with +1 charge. Those His are H2727.43 in the hAA3R
and H264EC3/ H2787.43in the hAA2AR.
1. Scanning the receptor for potential binding regions: Starting with the
predicted structure, we predicted putative ligands binding regions as
follows. We first alanized the entire protein (replacing the 6 hydrophobic
residues, I, L, V, F, Y, and W with A) and scanned for potential binding
regions with no assumption about the binding site. The entire molecular
surface of the predicted structure was mapped with spheres representing
the empty volume of the protein (currently using the Sphgen procedure in
DOCK4.0 suite of programs). The entire set of protein spheres is
partitioned into ~30 to 50 overlapping cubes of 10 to 14 Å sides. We then
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generated 1,000 poses for each of these 30 - 50 regions. These results are
compared to select the most promising two or three putative binding
regions.
2. DarwinDock: Our earlier studies used the HierDock and GenMSCDock,
which have now been replaced by DarwinDock. For each ligand
conformation, DarwinDock iteratively generates ~50,000 poses into the
putative binding regions of the bulky-residue-alanized protein. This is
followed by the E scoring of family heads to select the top 10% ordered by
total E. The top 100 conformations are chosen for further optimization.
For each of these we dealanize the protein side-chains (using SCREAM)
to find the optimum side chains for each of the best 100 poses. Then we
neutralize the protein and ligand by transferring protons appropriately
within salt bridges and protonating or deprotonating exterior ligands,
followed by further full geometry minimization.
This same procedure was followed for each of 7 ligand conformations
generated as follows. Starting from the x-ray structure of adenosine
crystal, we rotated the torsion angles Car-Car-NH-Cal and Car-NH-Cal-Car
between the adenine ring and the benzyl substituent by 60 ° increments to
generate 36 conformations. These were generated with the Maestro
software and minimized with the D3FF. We selected the lowest 7 ligand
conformations (within 3 kcal/mol of the best E) for docking in Table S2 of
Supporting Information as described above. The final docked structure
with the best binding E from all ligand conformations was selected.
DarwinDock has been validated for a number of x-ray co-crystals
including 3 crystal structures of ligand/ GPCR complexes: human β2-
adrenergic receptor (0.4 Å RMSD),10 human AA2AR (0.8 Å RMSD),9 and
turkey β1-adrenergic receptor (0.1 Å RMSD).8 This shows that we can
accurately identify ligand binding sites in proteins, which can then be used
to optimize the ligands with desirable properties.
3. Neutralization for scoring E: Quantum mechanics (QM) calculations
show that for an effective dielectric constant is < 8Å, the extra proton on a
Lys or Arg transfers back to the negative carboxylate of an Asp or Glu.22
Thus we expect that buried salt bridges will have neutral residues. We
consider that use of these neutral residue charges improves the accuracy
for comparing different docked structures. Of course the final bond energy
relative to ligand in the solvent and binding site exposed to solvent must
be corrected by the effective pK of the bare Lys, Arg, Glu, Asp or of the
ligand, a correction that is simple to make. For example, if the pK of a
carboxylate is 4.5 and the solvent is taken to have a pH of 7.4 we must
correct by 2.9*1.38 kcal/mol.
For external residues not involved in binding, we find it expedient to
neutralize the external residues exposed to solvent or membrane. Here the
issue is that the force fields commonly used in MD calculations involve
fixed charges, usually based on QM. In reality any net partial charges are
shielded by the dielectric polarization of the surrounding protein and
solvent so that there is negligible effect by 10Å. However with fixed
charges the electrostatic interaction energy between two point charges
separated by 10Å is 33 kcal/mol. The result is that small changes in
geometries of charged ligands far from the binding site can lead to large
differential binding energies, even 10 to 30 kcal/mol. We find that
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neutralizing these exposed residues removes the sensitivity to details of
the distances of charged residues (and counter ions) remote from the
active site. This neutralization leads to differential binding energies that
are dominated by the local cavity interactions and leads to much smaller
solvation energies.
6. MD studies
In order to validate the stability of the Monte Carlo structures predicted herein,
each ligand-protein predicted structure was inserted into a fully equilibrated
hydrated POPC lipid bilayer having cell size in the XY plane of 75 Å x75 Å (172
POPC molecules) and solvated with 6,689 water molecules using Membrane
builder in the VMD program. This was done for predicted structure 1 of the LJ1251
antagonist bound to predicted structure 2 and the Cl-IB-MECA agonist bound to
predicted structure 15 with the disulfide bridge between 88 and 166. The procedure
here was identical to that in Kim. et al.32
The lipid tails were almost fully extended, allowing for easy insertion of the protein
into the membrane. The distance between the layers was set at c=72.3 Å to fit the
actual membrane thickness plus the solvent thickness. The lateral supercell was set
to fit the actual surface density of lipid molecules, a=69.9 and b=68.4 Å. We
introduced disorder into the lipid bilayer patches to better resemble a membrane at
300K by allowing random orientation of each lipid about its axis with a short (1ps)
equilibration at 300K in vacuum. This eliminated steric contacts between the lipid
atoms but left the lipid tails mostly extended. These steps in our procedure reduce
the time required for equilibration of the lipid/protein complex. After inserting the
protein into the lipid-water cell, lipids overlapping within 1 Å of protein and waters
overlapping within 5 Å were removed.
For the particle mesh Ewald (PME) in the electrostatics calculation,33 the charge of
system was balanced through replacing waters into 13 Cl- ions. These systems
contain 37,661 atoms (A3 selective agonist Cl-IB-MECA-hAA3R), and 367,645
atoms (A3 selective antagonist LJ1251-hAA3R). This predicted structure was then
equilibrated at 300K for 1 ns using the NAMD 2.5 (NAnoscale Molecular
Dynamics) program.34 We used the CHARMM22 force field parameters for the
protein, the TIP3 model for water,35 and the CHARMM27 force field parameters
for the lipids.36 Minimization of both ligands in vacuum for these ligands led to
bond lengths, angles, and dihedrals similar to the quantum mechanical results and
the previous predicted structures determined with DREIDING.31 Quantum charges
from DFT/6311G** method were used for these ligands.
Results and Discussions
1. GEnSeMBLE predictions of the ensemble of low lying conformations of all four ARs
As summarized in Methods, the GEnSeMBLE method for predicting 3D structures of
GPCRs aims at sampling a complete set of helix conformation with the emphasis on the
rotations of the helices about their axis and on the tilts of these helices and then selecting the
top ~20 based on energetic. We start with a template to define the six degrees of freedom for
each helix (x, y, z, θ, φ, η) for each of the 7 helices and first consider all possible rotation
angles (η) about the helix axes. Generally GEnSeMBLE allows each η angle to go over
360°, in increments of 30°, leading to (7)12 = 35,000,000 different combinations. However,
for the ARs, we considered each η angle from -45° to +45° in 15° increments leading to (7)7
= 823,000 combinations. This is because an x-ray structure was available for hAA2AR and
the similarity of the four subtypes from the multiple sequence alignment in Fig. 1 suggests
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that the rotational angles would change by less than 45°. Supporting this, the analysis of
relative differences of the six degrees of freedom for each helix (x, y, z, θ, φ, η) among the
x-ray structures of GPCRs, β1 and β2 adrenergic receptor between two subtypes differs less
than ±10 ° in the rotational (η) angle of each helix, as shown in Table S3. Indeed despite the
major differences between hAA2AR and human β2 adrenergic receptor, the variation of the
rotational (η) angle of each helix is within ±20 °. In addition, the comparison of bovine
rhodopsin to opsin (which is believed to be an equilibrium active state structure) suggests a
range of ±30 ° in rotational angle variations (Table S4). Thus, our sampling angle of ±45 °
can generate the ground-state structure as well as the active state structure.
As described in Methods, we used the BiHelix mean field strategy to rapidly estimate the
energies of the 823,000 packings, selecting the lowest E 1000 to build into full 7-TMH
bundles with optimum side chains (CombiHelix). The top 10 predicted structures of
hAA2AR and hAA3R ranked by neutral total E are shown in Table 1. The other top 10
predicted structures of hAA1R and hAA2BR are displayed in Table S5. We find that the best
packing predicted structure for hAA2AR has exactly the same rotation angles as the
experimental hAA2AR (denoted as the all-0° predicted structure).
The same procedure was used for all four subtypes, but except for hAA3R, all ARs prefer
the same η=0° angles as hAA2AR.
For hAA2AR, we find that the top 10 predicted structures have variations of ± 15° for TMHs
1 and 4 and +15° for TMHs 3, 5, and 6.
For hAA1R we find that the top 10 predicted structures have variations of +15° for TMHs 3
and 7, ± 15° for TMH5, +15/ +45° for TMH6, and ± 15/ +30° for TMH4.
For hAA2BR we find helix rotation preferences similar to hAA2AR (reasonable based on the
sequence identity of ~60% in the TMH region between these two ARs), with rotational
variations of +15° for TMHs 4 and 6, ± 15° for TMH5, and -15 ° for TMH1.
For hAA3R, the lowest E predicted structure has TMH4-rotated by +15°. The top 10
predicted structures show rotational variations of -15° for TMHs 2 and 7, +15° for TMH3, ±
15° for TMH4, and +15, +30 ° for TMH6.
After determining the range of optimum η angles for the top 10 conformations of the four
subtypes, we then optimized the θ (tilt) and φ (sweep) angles. Here we started with the η’s
of the best conformation and varied η and φ over the range of -30, -15, 0, 15, 30 ° while
sampling θ for -10, 0, 10°. This leads to (75)7 = ~13 trillion (13,348,388,671,875)
combinations. To make it practical to estimate the energies of all these packings, we used
the SuperBiHelix mean field strategy described in the methods sections. Here we select the
best 2000 conformations to build into full 7-TMH bundles with optimum side chains,
selecting the best based on E for subsequent docking. These results for hAA3R are shown in
Table 2 where the all 0° predicted structure corresponds to the best predicted structure from
CombiBiHelix, which had TMH4 rotated 15°. Among the top 20 predicted structures for
hAA3R we find
η variations of -15° for TMHs 1 and 4
θ differences of -10° for TMH4 and +10° for TMH5.
φ changes of ± 15° for TMHs 4 and 7, 15° for TMH5, and ± 15, -30° for TMH6.
Thus there are favorable variations at TMHs 4, 5, 6, 7 within +15°. The various salt-bridges
and the H-bonding networks of the predicted structure in the D(E)RY and NPxxY region are
summarized in Table S6. Among these top 20 predicted structures, we find an average of 10
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inter-helical hydrogen bonds (HB). A3 has a specific H-bonding network among Y1093.51,
K1133.55 and D1995.60. These interactions are not observed in the x-ray structure of
hAA2AR, because the amino acid corresponding to D1905.60 in hAA3R is Arg in hAA2AR.
The 15th predicted structure of apo-A3 that is best for binding of selective agonists shows a
weakened interaction of TMHs 1-2-7 H-bonding networks among N301.50, D582.50, and
N2787.49, as shown in Table S6. The H-bonding distances of N301.50: N2787.49 and D582.50:
N2787.49 are 4.6 and 4.9 Å, respectively, while the corresponding H-bond distances in the
1st and 2nd model are 2.9 and 2.7 Å, respectively. However the salt-bridge and the H-
bonding in the D(E)RY region (D1073.49: R1113.53, D1073.49: R1264.41, R1083.50: E2256.30,
E2256.30: R2246.29 K1133.55: D1995.60, Y1093.51: K1133.55) are similar among them.
We show below that several of these best 20 predicted structures might play a role in
differential binding of agonists, antagonists, and inverse agonists, as well as in activation
pathways.
2. Ensemble docking of hAA3R selective agonists
We then docked the hAA3R selective agonists and selective antagonists in Chart 1 to each of
the best 20 predicted structures in Table 2 from SuperBiHelix.
We found variations in the orientation and packing of several of the TMH (especially TMHs
4, 5, 6, 7) in the top 20 predicted structures as follows: tilting ±10° for TMHs 4 and 5 ,
sweeping angles of ± 15° for TMHs 4/ 5 and ± 15, -30° for TMHs 6/ 7 , and rotation of -15°
for TMHs 1/ 4.
As shown in Table 3 and Fig. 2, we find that all four agonists,
• Cl-IB-MECA,
• IB-MECA,
• MRS1898 ((1’S, 2’R, 3’S, 4’R, 5’S)-4-{2-Iodo-6-[(3-iodophenylmethyl)amino]-
purine-9-yl}-1-(methylaminocarbonyl)bicycle-[3.1.0]-hexame-2,3-diol), and
• MRS3558 ((1’S, 2’R, 3’S, 4’R, 5’S)-4-{2-Chloro-6-[(3-iodophenylmethyl)amino]-
purine-9-yl}-1-(methylaminocarbonyl)bicycle-[3.1.0]-hexame-2,3-diol),
prefer to bind to the 15th lowest conformation from SuperBiHelix (TMH4 φ: -15°, TMH6 φ:
15°, TMH4 η: -15°).
3. Ensemble docking of hAA3R selective antagonist
On the other hand three antagonists,
• MRS3771 [(2S,3S,4R,5R)-5-[2-Chloro-6-(3-iodo-benzylamino)-purin-9-yl]-3,4-
dihydroxy-tetrahydrofuran-2-carboxylic acid dimethylamide],
• LJ1251 [(2R, 3R, 4S)-2-(2-Chloro-6-(3-iodobenzylamino)-9H-purin-9-
yl)tetrahydrothiophene-3,4-diol] and
• MRS1292 [(2R, 3R, 4S, 5S)-2-[N6-3-Iodobenzyl]adenos-9’-yl]-7-aza-1-oxa-6-
oxospiro[4.4]-nonan-4,5-diol],
prefer to bind to the predicted structure 2 from Table 3 (TMH6 φ: 15°, TMH4 η: -15°).
whereas antagonist
• MRS5127 [(1’R, 2’R, 3’S, 4’R, 5’S)-4’-[2-chloro-6-(3-iodobenylamino)-purine]-2’,
3’-O-dihydroxybicyclo-[3.1.0]-hexane],
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prefers predicted structure 3 with TMH4 φ: 15°, TMH6 φ: -30°, TMH4 η: -15°. The second
best predicted structure for MRS5127 is also predicted structure 2 of Table 1.
This exception of MRS5127 might arise from a different signaling system. MRS5127 was
highly AA3R-selective (Binding affinity at three human AR subtypes: hA1 = 3040 ± 610
nM, hA2A = 1080 ± 310 nM, hA3 = 1.44 ± 0.6 nM). By Schild analysis of [35S]GTPγS
binding to membranes from CHO (Chinese Hamster Overlay) cells expressing the hAA3R,
MRS5127 appeared to be an antagonist.37 However, further analysis determined that it is a
partial agonist stimulating cAMP (cyclic adenosine monophosphate) production in
transfected cells with 45% efficacy compared to the full agonist NECA (Adenosine 5’-N-
ethyluronamide).38
LJ1251 acts more uniformly as an antagonist both in GTPγS binding and in cyclase
experiments, but MRS5127 leads to differences in the functional assay.
4. Comparison of conformations for binding agonists and antagonists
The 20 most stable predicted structures for the apo protein all have a gauche+ χ1 rotamer
preference for W6.48 (leading to the vertical orientation with respect to the membrane
plane) that has been implicated from experiments on other GPCRs to be associated with the
inactive form. 8-10
We predicted the bound structure of the agonist (Cl-IB-MECA) to each of these predicted 20
lowest apo-hAA3R structures and found that the predicted best structure (to apo-15) and
60% of the 20 show a preference of W6.48 for the trans χ1 rotamer (leading to the
horizontal orientation with respect to the membrane plane). Previous experiments on other
GPCRs have indicated that the trans χ1 rotamer W6.48 is involved in activation.39,40
These results indicate that the mere binding the agonist to the apo-hAA3R structure already
can reposition the W6.48 conformation from the inactive form to the active form. This may
prepare the agonist bound protein for a step that leads to activation, and hence it could be
involved in activation as suggested by experiments on other GPCRs.39.40
Previous experiments on other GPCRs have also suggested that Y7.53 and R3.50 might also
serve as rotamer switch upon activation.41 However, considering each of the top 20
predicted apo-hAA3R structures bound to either agonists or antagonists, Table S7 in
Supporting Information, shows that the χ1 angles of Y2827.53 and R1083.50 in the ligand-
bound predicted structures have values nearly identical to the apo-protein. Thus the χ1 angle
of Y2827.53 is -65° in apo- and antagonist-hAA3R and -68° for agonist-hAA3R. Similarly
the χ1 angle of R1083.50 is -74° in apo-hAA3R, -73° in antagonist-hAA3R and -73° for
agonist-hAA3R. This can be compared to the χ1 angles of are -74.31 for Y2827.53 and -81.43
° for R1083.50 in opsin (PDB ID: 3cap). It may be that the Y7.53 and R3.50 residues play a
later step in activation not sampled by our ensemble of structures and dynamics or it may be
that hAA3R does not involve these toggling events.
Fig. S3 compares the best predicted structure for agonist Cl-IB-MECA/hAA3R to the opsin
crystal structure. Here we see similar values for the orientation of the three toggle switch
residues, W2436.48, Y2827.53, and R1083.50. This would suggest that in our apo protein
structures, Y2827.53 and R1083.50 are already in their active form.
Table S7 shows that for apo-hAA3R the top 20 predicted structures from SuperBihelix all
have the gauche+ χ1 rotamers of W6.48.
Table 3 shows that the best conformation (#15 of apo-hAA3R) for all four agonists has the
trans χ1 conformation of W6.48. Indeed, this conformation is found in 12 of the top 20 in
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the Cl-IB-MECA and IB-MECA-hAA3Rs and in 6 of the top 20 for the MRS1898 and
MRS350-hAA3Rs.
Similarly Table 3 shows that the 5’-truncated antagonists, MRS5127 and LJ1251, docked to
hAA3R all show gauche+ χ1 rotamers of W6.48 (conformation 2). In contrast the 5’-
modifed MRS3771 and MRS1292 prefer the trans χ1 conformation.
Fig. 3 shows the predicted structure 15 of agonist Cl-IB-MECA and the predicted structure 2
of the antagonist LJ1251 which features strongest interactions with the ligand molecule from
DarwinDock (Table 3). The orientation of the W6.48 side chain in the agonist-bound
hAA3R is toward TMH5, while the W6.48 in the antagonist bound hAA3R, is the same as in
the apo-protein, which interacts with the NPxxY motif. That is, the agonists all induce a
rotamer switch of W6.48 during upon binding. Indeed we find that the agonist-bound
predicted structures are highly unfavorable in the gauche+ χ1 conformation of W6.48. Thus
Fig. 4 shows how the total cavity E depends on a trans vs. gauche+ χ1 rotamer of W6.48.
All agonist-bound complexes lead to an increase in the E of > ~12 kcal/mol in the gauche+
χ1 form of W6.48 due to steric bumps with 5’-substituents.
In contrast, we find the antagonist-bound predicted structures lead to similar cavity energies
for both conformations. For nucleoside antagonists containing 5’-substituents (MRS1292
with 5’-cyclized uronamide and MRS3771 with 5’-N,N-dimethyl uronamide) are ~3 kcal/
mol unfavorable in the gauche+ χ1 form of W6.48. However, MRS5127 and LJ1251, which
are truncated at the 5’-position, are more stable in the gauche+ χ1 conformation of W6.48.
The predicted rotamer switch of W2436.48 induced by binding of the agonist found in this
study is consistent with some experimental observations.42 Thus the W243A mutation in
hAA3R dramatically impaired functional coupling but did not diminish agonist affinity. Also
W243F affected function but did not diminish agonist affinity. Thus we conclude that
binding the agonist induces reorientation of the W2436.48 side chain which affects the
receptor’s transition from an inactive to an active state.
We find specific interactions of the ribose moiety in its hydrophilic pocket at T3.36, S7.42,
and H7.43. This complex is stabilized by inward movement of F5.43 and the characteristic
outward rotation of W6.48 as found in previous docking studies.43
Several previous studies on various GPCRs have suggested that W6.48 functions as a
rotamer toggle switch from inactive gauche+ to active trans. The available experimental 3D
structures of GPCRs bound to an inverse agonist or antagonist8-10, 29 all have W6.48
constrained in the inactive gauche+ conformation either by a network of interactions
through water (bRho and the β1, β2 adrenergic receptors) or by an extension of N7.45
(hAA2AR) to D2.50. The x-ray structure of metarhodopsin I suggests that W6.48 undergoes
a conformational transition during the process of receptor activation, where it shifts from
pointing toward TMH7 in the inactive gauche+ conformation to pointing toward TMH5 in
the active trans conformation.39 Based on the Conformational Memories biased Monte
Carlo technique it was concluded that rotamer changes of C/S/T6.47, W6.48, and F6.52 in
β2 adrenergic receptor are highly correlated, representing a rotamer “toggle switch” that may
modulate the TMH6 Pro-kink.44
On the other hand site-directed mutagenesis and molecular modeling approaches suggest
that the 5-hydroxytryptamine-4 receptor involves different side-chain conformational toggle
switches, i.e. T3.36 from inactive gauche- to active gauche+ and W6.48 from inactive
gauche+ to active trans.40
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5. MD on ligand-protein in membrane and solvent
The above predictions represented the presence of the membrane and water using implicit
solvation methods. To test the effect of explicit interactions with membrane and solvent, we
inserted each ligand-protein predicted structure into a fully equilibrated hydrated palmitoyl-
oleyl-phosphatidylcholine (POPC) lipid bilayer and water, which was subsequently
equilibrated for 10 nanoseconds. All charged residues (Asp, Glu, Lys, and Arg) were treated
as charged amino acids with CHARMM22 force field parameters.35
The potential E (Fig. S4 in Supporting Information) shows reasonable convergence in 10 ns,
suggesting that the predicted structures are reasonably close to a local minimum.
In particular for the agonists the MD finds that the 15th lowest predicted structure (average
RMSD of protein and ligand: 1.5 and 1.3 Å) remains more stable than the first predicted
structure (average RMSD of protein and ligand: 2.3 and 2.6 Å), while for the antagonist the
second predicted structure (average RMSD of protein and ligand: 2.1 and 1.9 Å) remains
more stable than the first predicted structure (average RMSD of protein and ligand: 2.6 and
2.1 Å).
Our predicted structures lead to no significant changes in the salt-bridges or polar contacts
for these cases. However, for the agonist Cl-IB-MECA/ hAA3R complex, we found
increased stability of the salt-bridge between D1073.49 and R1264.41 compared with LJ1251/
hAA3R complex. The predicted salt bridge from R1083.50 of the D(E)RY motif of TMH3
with E2256.30 of TMH6 remains intact during these dynamics (Fig. S5 in Supporting
Information).
As shown in Fig. 5, the W6.48 rotamer for both agonist and antagonist retains the same
conformation (horizontal for agonist vs. vertical for antagonist) during the dynamics. We
found no significant changes in the salt-bridges or polar contacts for these cases in the
predicted structures.
These limited MD studies validate the local stability of the predicted structures. However,
we anticipate that it will take much longer dynamics (perhaps 1 to 1000 microseconds) to
observe the changes involved with activation.
6. Subtype selectivity through docking studies using the DarwinDock method
As summarized in Methods the DarwinDock method for predicting ligand binding sites,
starts by sampling the full protein to locate putative binding regions, and then aims at
sampling a complete set of ligand conformation for each of which we sample a complete set
of poses, from which we use the total binding E to select the best poses.
6.1 hAA2AR selective adenosine—Since adenosine has ~ 30 fold higher selectivity to
hAA2AR than hAA3R, we docked adenosine, the endogenous agonist, to the lowest E
predicted structure of hAA2AR of Table 1. Table S8 in Supporting Information lists the final
25 poses out of the 5,000 conformations generated by DarwinDock
All poses show similar ribose packing, and indeed nearly all adenosine agonists maintain
similar ribose moieties, except for the amide substitution at the 5’-position. Indeed an intact
furanose moiety is present in most potent adenosine agonists previously developed.45 Our
cavity analysis (see Table 4) of the adenosine bound to hAA2AR shows that the three major
contributing amino acids are N2536.55 (-7.22 kcal/mol), F168EL2 (-6.33 kcal/mol), and
E169EL2 (-5.13 kcal/mol), based on non-bonding energies [defined in the methods section as
the sum of vdW, electrostatic Coulomb with 2.5 dielectric constant and H-bond energies].
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In the predicted structure of adenosine-hAA2AR, we find that the exo-cyclic amino group of
the adenine ring interacts with N2536.55 and E169EL2 in the same way that it interacts with
the amino group in the tri-cyclic ring of ZM241385 seen in the x-ray structure of hAA2AR,
as shown in Fig. 6A and 7A. An additional predicted interaction (-2.82 kcal/mol) occurs
between the 2’ and 3’-OH group of the nucleoside ring and the side chains of the double
protonated basic H2787.43, which also interacts with E131.39. Supporting this, the Ala
mutation of N2536.55 shows loss of agonist and antagonist binding, while the H278E7.43
mutation displays substantial decrease of agonist and antagonist binding except in the case
of N6-substituted agonists.46
We then matched the predicted ligand binding structure from hAA2AR to hAA3R, leading to
common interactions at N2506.55 (-5.82 kcal/mol), F168EL2 (-4.52 kcal/mol), and H2727.43
(-4.03 kcal/mol). However, V169EL2 in hAA3R corresponds with E169EL2 in hAA2AR
losing the interaction with the terminal amino group, resulting in unfavorable interactions in
hAA3R because of the different loop geometry of EL2 (Table 4 and Fig. 7B). The result is a
dramatic decrease in binding affinity (cavity sum = -37.56 for hAA2AR vs. -28.92 for
hAA3R) in agreement with the dramatically decreased experimental binding affinity of
endogenous adenosine at both rat ARs (rAA2AR estimated Ki: 30 nM vs. rAA3R estimated
Ki, 1,000 nM).45
6.2 hAA3R selective Cl-IB-MECA agonist—We docked Cl-IB-MECA to the lowest E
predicted structure of hAA3R of Table 1. From DarwinDock we selected the final 125 poses
(five different ligand conformations with 25 poses each) out of 25,000 conformations. These
predicted structures were ordered by the average rank of neutral total and Unified cavity E
(UniCav E) in Table S9 in Supporting Information. From the cavity analysis of A3 subtype
selective Cl-IB-MECA bound to hAA3R, Table 5 shows that the major contributing amino
acids are F168EL2 (-9.79 kcal/mol), N2506.55 (-4.44 kcal/mol), L2466.51 (-4.28 kcal/mol),
and H2727.43 (-3.35 kcal/mol). The terminal benzyl group of Cl-IB-MECA is surrounded by
hydrophobic residues, V169EL2 and I2536.58, as shown in Fig. 6B and 7D. The N6-bulky
group extends an additional interaction between EL2 and upper TMH6, making stronger
interactions at hAA3R.
To understand the origin of subtype selectivity, we matched the predicted best binding pose
of the highly A3-selective ligand Cl-IB-MECA to the hAA2AR predicted structure, and then
we used SCREAM28 to predict the optimum side chain position of residues in the binding
pocket, after which we minimized the final ligand/protein complex post neutralization. In
hAA2AR, the residue-ligand interactions were hampered by the constrained loop between
E169EL2 and H264EL3 via a salt-bridge, as shown in Fig. 7C. The corresponding amino
acids of I2536.58, V169EL2, and Q167EL2 in hAA3R are T2566.58, E169EL2, and L167EL2 in
hAA2AR. All three subtype variable residues in hAA2AR show weakened interactions in the
cavity of hAA2AR in Table 5, resulting in a 7.31 kcal/mol favorable interaction in hAA3R.
This predicted structure is consistent with the experimental binding affinity of A3 subtype
selective Cl-IB-MECA (AA3R Ki: 1.4 nM vs. AA2AR Ki, 5,360 nM).47 The docking result
also agrees with experimental observations, where the subtype selectivity of adenosine
derivatives as AR agonists has been probed extensively, principally through modification of
the N6-amine moiety (where large hydrophobic groups tend to produce AA1R and AA3R
selectivity) and the C2 position (where large hydrophobic groups tend to produce AA2AR
selectivity).48
Based on the docking studies of the subtype selective antagonists, we suggest that I2536.58
and V169EL2 in hAA3R are involved in vdw interactions with the N6-bulky group in the A3
selective ligands, while E169EL2 in hAA2AR (which is the corresponding amino acid of
V169EL2 in hAA3R) interacts with the free amino group of the A2A selective ligands
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through additional H-bonding. Thus this predicted structure explains the increase of A3
selectivity for the additional N6-bulky substituent at hAA3R. However, Q167EL2 in hAA3R
is located in the proximity of the C2 substituent which is oriented toward the EC2 in the
docking model. The corresponding amino acid L167EL2 in hAA2AR might explain the
increase of A2A selectivity for large hydrophobic C2 substituents which are found in most
A2A selective antagonists.48
Conclusions
We used the GEnSeMBLE Monte Carlo Technique to predict an ensemble of the 20 top
apo-protein predicted structures for all 4 subtypes of the human adenosine receptor. For
hAA3R we used the DarwinDock Monte Carlo Technique to predict the best binding pose
for four subtype selective agonists and antagonists.
We find that all four selective agonists prefer what was the 15th predicted structure of the
apo protein. In addition, all four change the W6.48 conformational state from gauche+
(vertical) to trans (horizontal). This is consistent with observations in other GPCRs that
switching of W6.48 from gauche+ (vertical) to trans (horizontal) is associated with
activation of the G-Protein.
In contrast the four selective antagonists all prefer ether the 2nd or 3rd conformation of the
apo protein. However the situation with respect to the toggle switch is mixed. MRS5127 and
LJ1251, for which the ribose is dramatically modified, retain the gauche+ conformational of
W6.48 found in the apo protein for all 20 low lying conformations. However MRS1292 and
MRS3771, which retain the ribose unit of the adenosine agonist but with substitutions for
the CH2OH, prefer the trans (active) conformation in the lowest E conformation, but has the
gauche+ conformation for various low lying cases.
These results provide strong support for the role of W6.48 as a rotamer toggle switch
affecting activation, suggesting that our methods have successfully found the ensemble of
low lying conformations relevant for ligand binding and for activation of the GPCR.
We also predicted the low lying conformations of the adenosine A2B, A1, and A3 receptors
subtypes finding:
1. Excellent agreement of subtype specificities for binding of the A3 selective Cl-IB-
MECA and A2A selective adenosine agonists between these two ARs.
2. Excellent agreement between the binding site of the adenosine agonist bound to
hAA2AR with available mutation data.
These results suggest that these computational methods can predict the ensemble of low
lying predicted structures accurately enough to extract information relevant for
understanding activation and accurately enough to predict the changes in conformation for
different subtypes. Moreover the detailed binding sites are accurate enough to predict the
differential binding characteristics between different subtypes and between agonists and
antagonists binding to the same subtype. This suggests that these methods may be useful for
designing subtype selective ligands for GPCR targets, even when no experimental structural
information is available.
The success of these studies relies in part on having an experimental structure of hAA2AR,
indicating the value of having a crystal structure of a related system. The theory can then
build on this structure to predict the structures of other subtypes. Moreover the theory can
then predict the structures for agonists not yet available from experiment.
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Abbreviation
AA3R Adenosine A3 receptor
GPCR G Protein-Coupled Receptor
vdW van der Waals
TMH transmembranic helix
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Figure 1.
Alignments of the four adenosine receptor (AR) subtypes, A1, A2A, A2B, and A3 from the
PredicTM method. The predicted TMH regions from PredicTM are displayed in colored
boxes (TMH1 in purple, TMH2 in blue, TMH3 in cyan, TMH4 in green, TMH5 in yellow,
TMH6 in orange, TMH7 in red), while the TMH region from the x-ray structure of the
AA2AR (PDB: 3eml) is underlined. Highly conserved residues in Family A G protein-
coupled receptors (GPCRs) are shown in red in TMH 1-6 and white in TMH7. Variable
amino acids among the four subtypes in the upper TMH regions are marked with red
asterisks and subtype selective residues predicted from the cavity analysis are boxed. The
disulfide bridges in yellow were assigned (A1: 80-169, 260-263, A2A: 71-159, 74-146,
77-166, 259-262, A2B: 72-167, 78-171, A3: 83-166) based on the sequence alignment. We
use Ballesteros-Weinstein numbering consisting of the TMH helix number followed by
residue number relative to the highly conserved residue in the helix, numbered as 50. H-
bonding is indicated by arrows, and subtype selective residues are shown in red.
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Figure 2.
Graphical summary of ensemble docking in Table 3. The relative energies for apo and
antagonist or agonist-bound human adenosine A3 receptors (hAA3R) are displayed. We find
that all four A3 selective agonists stabilize the 15th lowest conformation of hAA3R while
also binding strongly to the 1st and 3rd. In contrast three antagonists stabilize the 2nd lowest
conformation of hAA3R while antagonist MRS5127 prefers the 3rd but binding to the 2nd is
next best. Experimentally the function of MRS5127 is ambiguous. It appeared to be an
antagonist but acted as a partial agonist in cAMP (cyclic Adenosine monophosphate)
production in transfected cells with 45% efficacy compared to the full agonist NECA
(Adenosine 5’-N-ethyluronamide). All 20 lowest predicted structures for the apo hAA3R
have the “toggle switch” W6.48 in the gauche+ χ1 (NH-Cα-Cβ-Cγ) rotamer (tryptophan
plane perpendicular to the membrane plane) associated with the inactive G protein-coupled
receptor (GPCR) while the lowest predicted structures for the agonist bound state all have
the trans χ1 (NH-Cα-Cβ-Cγ) rotamer (tryptophan plane parallel to the membrane plane)
associated with the active GPCR. The situation is more ambiguous for the antagonist cases.
Here MRS5127 and LJ1251 retain gauche. The cases with this trans rotamer are denoted by
filled boxes while the cases with the gauche+ rotamer have open boxes. For cases in which
the boxes overlap, the higher energy one was shifted higher to avoid overlapping. These
cases are marked with asterisks.
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Figure 3.
Predicted best structures of selective nucleoside antagonist LJ1251 bound to adenosine A3
receptor (AA3R) (A), selective agonist Cl-IB-MECA bound to adenosine A3 receptor
(AA3R) (B) and superimposition of antagonist (blue)/ agonist (red) bound predicted
structures (C) without ligands. We predicted the binding to the top 20 predicted structures
from the SuperBihelix analysis of the apo-AA3R as shown in Table 3. LJ1251 binds to
predicted structure 2 of apo-AA3R while Cl-IB-MECA binds to predicted structure 15 of
apo-AA3R The orientation of the W6.48 side chain, shown in yellow, in the agonist-bound
hAA3R is perpendicular to the AA3R axis and toward TMH5, while its orientation in the
antagonist binding parallel to the AA3R axis allowing it to interacts with the NPxxY motif,
just as in the best predicted structure of the apo-AA3R.
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Figure 4.
The relative difference of total cavity energy depending on the trans vs. gauche+ χ1 (NH-
Cα-Cβ-Cγ) rotamer states of W6.48. All top agonist-bound complexes have over ~12 kcal/
mol higher E in the gauche+ χ1 form of W6.48 because of steric bumps with 5’-substituents.
However, all antagonist-bound predicted structures have similar energies for both
conformations. In the case of nucleoside antagonists with 5’-substituents, the 5’-cyclized
uronamide in MRS1292 and 5’-N,N-dimethyl uronamide in MRS3771 are < ~3 kcal/mol
unfavorable in the gauche+ χ1 form of W6.48. However, MRS5127 and LJ1251, which
were truncated at the 5’-position, are more stable in the gauche+ χ1 conformation of W6.48.
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Figure 5.
Molecular dynamics simulation of (A) antagonist LJ1251 in yellow and (B) agonist Cl-IB-
MECA in orange bound human adenosine A3 receptor (hAA3R) in explicit lipid and water.
Bottom) χ1 torsion angle (NH-Cα-Cβ-Cγ) variation of W2436.48 in green through 10 ns
simulations. Ligand at the beginning is represented by the stick model and ligand at 10ns is
shown in vdW (van der Waals) drawing mode of the VMD (Visual Molecular Dynamics)
program.
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Figure 6.
Schematic of the predicted binding sites for adenosine receptor agonists based on the cavity
binding energies. Left: adenosine at hAA2AR; Right: Cl-IB-MECA at hAA3R
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Figure 7.
Predicted binding sites (A) adenosine to the adenosine A2A receptor (AA2AR), (B)
adenosine to the adenosine A3 receptor (AA3R), (C) A3 selective agonist Cl-IB-MECA at
AA2AR, (D) A3 selective agonist Cl-IB-MECA at AA3Rs. The high selectivity of Cl-IB-
MECA for AA3R relative to AA2AR is due to the salt-bridge between E169 and H264 (red
circle in (C)) in AA3R. In AA2AR we have V169 but there is no residue corresponding to
H264 because of the gap in AA2AR. H-bonding is indicated by red dots, and subtype
selective residues are shown in red.
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Chart 1.
Structures of four agonists (Ag) and four antagonists (Ant) exhibiting selective binding to
the adenosine A3 receptor with respect to A2a. Binding affinities (Ki in nM) are shown for
A3 with relative efficacies in parenthesis compared to the endogenous adenosine.
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